Finance Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail DeFi Insurance Alternative Nexus M Finance Share Share this article Copy linkX (Twitter)LinkedInFacebookEmail DeFi Insurance Alternative Nexus M

DeFi Insurance Alternative Nexus Mutual Integrates Restaking Specialist Symbiotic

Share
Share this article
Copy linkX (Twitter)LinkedInFacebookEmail

DeFi Insurance Alternative Nexus Mutual Integrates Restaking Specialist Symbiotic

A new class of Symbiotic underwriting vaults will create a reinsurance layer to help scale Nexus Mutual.

By Ian Allison|Edited by Omkar Godbole
Updated Nov 19, 2025, 2:33 p.m. Published Nov 19, 2025, 6:32 a.m.
Inside the Lloyd's of London insurance market. (Lloyd's of London)

What to know:

  • Capital allocated via Symbiotic can now secure traditional proof-of-stake (PoS) networks while simultaneously underwriting Nexus coverage.
  • The partnership addresses a structural gap in DeFi risk coverage: the lack of scalable and transparent reinsurance infrastructure.

Decentralized insurance protocol Nexus Mutual, has integrated with restaking protocol Symbiotic to create a yield-generating reinsurance layer to underwrite decentralized finance risks.

The collaboration with Symbiotic, a restaking protocol designed to rival EigenLayer, introduces a new class of underwriting vaults aligned with Nexus cover durations, enabling real-time capital reallocation and fast claim settlement, according to a press release on Wednesday.

STORY CONTINUES BELOW
Don't miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters
Sign me up

Capital allocated via Symbiotic can now secure traditional proof-of-stake (PoS) networks while simultaneously underwriting Nexus coverage, helping scale the alternative insurance cover provider without introducing centralization or inefficiencies typical of legacy models, the release said.

“For years, onchain risk markets have struggled to scale because capital was fragmented across isolated pools,” said Misha Putiatin, co-founder of Symbiotic. “By introducing composable underwriting infrastructure, we’re unlocking scalable, permissionless risk markets where capital can finally work across multiple layers of the ecosystem. This isn’t just an improvement in efficiency, it's something that can finally get us to scale”

Nexus Mutual seeks to address the dire shortage of insurance capacity within the crypto industry by allowing members to deploy assets into syndicates, in a way similar to how the Lloyd’s of London market operates, for which they receive NXM tokens. These tokens are then used to back certain risks in return for yields which can reach around 25%, according to Nexus Mutual founder Hugh Karp.

The partnership addresses a structural gap in DeFi risk coverage: the lack of scalable and transparent reinsurance infrastructure. For Nexus Mutual, it opens doors to additional underwriting demand, allowing the protocol to expand coverage across protocols and asset classes without raising idle reserves.

“As there continues to be greater institutional adoption of DeFi, investors have been asking Nexus Mutual to cover risks at an even larger scale,” said Hugh Karp, Founder of Nexus Mutual. “By working with Symbiotic, we’re making sure our onchain cover solutions can fit the needs of any institutional investor or protocol.”

Nexus Mutual

More For You

Protocol Research: GoPlus Security

Commissioned byGoPlus

What to know:

  • As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.
  • GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.
  • Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.
View Full Report

More For You

Coinbase Debuts DEX Trading in Brazil as ‘Everything App’ Vision Grows

The move comes amid new regulations from Brazil's central bank, requiring crypto firms to be licensed and report international transactions.

What to know:

  • Coinbase is rolling out DEX trading in Brazil, offering access to a broader pool of tokens through platforms like Uniswap and Aerodrome.
  • The move comes amid new regulations from Brazil's central bank, requiring crypto firms to be licensed and report international transactions.
  • Coinbase's DEX feature is non-custodial, allowing users to manage trades through a self-custody wallet without paying network fees.
Read full story
Latest Crypto News

AI Agents Need Identity and Zero-Knowledge Proofs Are the Solution

Bitcoin Slips Back Below $90K — Crypto Correction Now Ranks Among Worst Since 2017, K33 Says

Stella's XLM Token Breaks Key $0.25 Support as Altcoins Suffer Continued Drawdown

Coinbase Debuts DEX Trading in Brazil as ‘Everything App’ Vision Grows

HBAR Slides 0.5% to $0.146 as Technical Support Crumbles

ICP Softens as Failed Breakout Above $5.17 Shifts Market Back Into Consolidation

Top Stories

Bitcoin Slips Back Below $90K — Crypto Correction Now Ranks Among Worst Since 2017, K33 Says

Senate Banking Panel Advances FDIC's Travis Hill for Wider Confirmation Vote

Winklevoss-Backed Cypherpunk Buys $18M More Zcash, Bringing Holdings to $150M

Bitcoin Market Watch: Nvidia Earnings, Fed Minutes and Payrolls to Set the Tone

Crypto ETFs Enter Maturity Phase as IRS and SEC Actions Drive Rapid Expansion of Products

Apex Group Said to Buy Broker Dealer Globacap for U.S. Tokenization Push

Market Opportunity
DeFi Logo
DeFi Price(DEFI)
$0,000433
$0,000433$0,000433
-5,04%
USD
DeFi (DEFI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26